Nanotechnology-based delivery systems to overcome drug resistance in cancer

Abstract

Cancer nanomedicine is defined as the application of nanotechnology and nanomaterials for the formulation of cancer therapeutics that can overcome the impediments and restrictions of traditional chemotherapeutics. Multidrug resistance (MDR) in cancer cells can be defined as a decrease or abrogation in the efficacy of anticancer drugs that have different molecular structures and mechanisms of action and is one of the primary causes of therapeutic failure. There have been successes in the development of cancer nanomedicine to overcome MDR; however, relatively few of these formulations have been approved by the United States Food and Drug Administration for the treatment of cancer. This is primarily due to the paucity of knowledge about nanotechnology and the fundamental biology of cancer cells. Here, we discuss the advances, types of nanomedicines, and the challenges regarding the translation of in vitro to in vivo results and their relevance to effective therapies.

Harnessing the Power of Polyphenols: A New Frontier in Disease Prevention and Therapy

“…Enterocytes and hepatocytes can hydrolyze and biotransform simpler polyphenolic substances after absorption. Hydrophilic conjugated metabolites such as methyl, glucuronide, and sulfate derivatives are then rapidly released into the bloodstream, transported to various organs, or eliminated in urine [ 23 , 24 , 25 ]. The potential formation of new compounds during the metabolism of each phenolic molecule complicates tracing individual compounds in the body [ 26 ].…”

Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research

“…Tailorable nanoengineered drug conveyance systems, encompassing nanoparticles, liposomes, and dendrimers, can be designed to accumulate in tumors either through passive means (leveraging the enhanced permeability and retention effect) or actively (via the attachment of specific molecules or antibodies). This targeted strategy serves to diminish side effects while amplifying the efficacy of cancer therapies [ 3 ].…”